# US 2018/0021430 A1 · Selective targeting of the cd40l/mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021430 A1
- Document ID: US20180021430A1
- Status: Published application
- Kind: A1
- Application number: 15/710,292
- Filed: 2017-09-20
- Published: 2018-01-25
- Earliest claimed: 2010-10-21
- Assignees: Universitaetsklinikum Freiburg; Baker IDI Heart and Diabetes Institute Holdings Limited
- Applicants: Universitaetsklinikum Freiburg; Baker IDI Heart & Diabetes Institute Holdings Ltd.
- Inventors: Andreas ZIRLIK; Dennis WOLF; Karlheinz PETER
- Web page: https://patentgrep.com/patent/US20180021430A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/1709: {from mammals}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/2845: {against integrin beta2-subunit-containing molecules, e.g. CD11, CD18}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.

## Claims

### Claim 1

An antibody capable of specifically binding to an epitope comprising the amino acid sequence QLK.

### Claim 2 (depends on 1)

The antibody according to claim 1, capable of specifically binding to an epitope comprising at least part of the amino acid sequence SEQ ID NO:19.

### Claim 3 (depends on 1)

The antibody according to claim 1, capable of specifically binding to an epitope comprising at least part of the amino acid sequence SEQ ID NO:20.

### Claim 4 (depends on 1)

The antibody according to claim 1, capable of specifically binding to an epitope comprising at least part of the amino acid sequence SEQ ID NO:3.

### Claim 5 (depends on 1)

The antibody according to claim 1, capable of specifically binding to an epitope comprising at least part of the amino acid sequence SEQ ID NO:1.

### Claim 6 (depends on 1)

The antibody according to claim 1, capable of specifically binding to an epitope comprising at least part of the amino acid sequence SEQ ID NO:2.

### Claim 7

An antibody capable of inhibiting the binding of macrophage-1 antigen (Mac-1) to CD40L.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising the antibody according to claim 1.

### Claim 9 (depends on 8)

A process for the treatment of an atherosclerotic disease comprising administering the pharmaceutical composition according to claim 8 to a subject in need thereof.
